EC
NTLA icon

EntryPoint Capital’s Intellia Therapeutics NTLA Stock Holding History

EntryPoint Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-32,425
Closed -$378K – 867
2024
Q4 		$378K Buy
+32,425
New +$506K 0.16% 232
2024
Q3 		– Sell
-322
Closed -$7.21K – 972
2024
Q2 		$7.21K Sell
322
-3,800
-92% -$90.5K 0.01% 777
2024
Q1 		$113K Buy
4,122
+1,563
+61% +$43.4K 0.1% 344
2023
Q4 		$78K Buy
+2,559
New +$73.5K 0.07% 503

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EntryPoint Capital's NTLA Position: Q1 2025 in Review

EntryPoint Capital sold out of Intellia Therapeutics (NTLA) in Q1 2025, closing a stake of 32,425 shares — an estimated $378K sold.

EntryPoint Capital first reported a position in NTLA in Q4 2023 and held it in 4 quarters. The position peaked at $378K in Q4 2024. 294 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.

  • EntryPoint Capital reported no remaining Intellia Therapeutics position as of Q1 2025 after selling out during the quarter.
  • EntryPoint Capital sold 32,425 Intellia Therapeutics shares in Q1 2025, an estimated $378K.
  • EntryPoint Capital first reported a position in Intellia Therapeutics in Q4 2023 and held it in 4 quarters.
  • EntryPoint Capital's Intellia Therapeutics position peaked at $378K in Q4 2024.
  • 294 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.

Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.